1-3 of 3
Judy S. Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors

Melissa L. Johnson, Beni B. Wolf, Judy S. Wang, Alexander Philipovskiy, Geoffrey I. Shapiro, Bruno Bockorny, Wei Guo, Jinshan Shen, Kai Yu Jen, MaryBeth LeRose, Tamieka Lauz Hunter, Mahesh Padval, Oleg Schmidt-Kittler, Namrata Bhatia, Sarita Dubey, Julia Suchomel, Johanna C. Bendell, Shekeab Jauhari, Jennifer Eng-Wong, Jessica J. Lin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF8.
https://doi.org/10.1158/1535-7163.MCT-24-0466
Published: 31 December 2024
View article titled, First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors
Open the PDF for First Results of Migoprotafib, a Potent and Highly Selective Src Homology-2 Domain–Containing Phosphatase 2 Inhibitor in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors

Elisa Fontana, Babar Bashir, Judy S. Wang, Raid Aljumaily, Jean-Pascal Machiels, Maria Vieito, Gerald Falchook, Louise Carter, Bernard Doger de Spéville, Alastair Greystoke, Sang Wun Kim, Nuria Kotecki, Alexander I. Spira, Irene Moreno Candilejo, Bristi Basu, Hans Prenen, Alberto Bessudo, Misako Nagasaka, Jordi Rodón Ahnert, Joo-Hwan Park, Min-Yuen Teo, Julia Rotow, Jie Liu, Assunta De Rienzo, Mengyao Li, Adriana Domingo, Hanna Orr, Gavin Bennett, Rajiv Sharma, Meredith McKean
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): LB_A17.
https://doi.org/10.1158/1535-7163.TARG-23-LB_A17
Published: 01 December 2023
View article titled, Abstract LB_A17: Trial in progress: First-in-human phase I dose-escalation study of a novel Bicycle toxin conjugate (BT5528) targeting EphA2 in patients with advanced solid tumors
Journal Articles

First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

Erika P. Hamilton, Judy S. Wang, Amit M. Oza, Manish R. Patel, Susanna V. Ulahannan, Todd Bauer, Janet L. Karlix, Jorge Zeron-Medina, Giulia Fabbri, Paola Marco-Casanova, Ganesh Moorthy, Maureen M. Hattersley, Gillian M. Littlewood, Patrick Mitchell, Jamal Saeh, Gayle P. Pouliot, Kathleen N. Moore
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (10): 1154–1165.
https://doi.org/10.1158/1535-7163.MCT-23-0065
Published: 02 October 2023
View article titled, First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma
Open the PDF for First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma in another window
Includes: Supplementary data